Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers

CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer

(2022) Jan Korbecki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques

(2022) Ju-Hyun Lee et al.   NATURE NEUROSCIENCE

The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm

(2022) Longsha Liu et al.   JAMA Oncology

METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer

(2022) Huarong Chen et al.   GASTROENTEROLOGY

The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature

(2021) Jan Korbecki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy

(2021) Pedro Bule et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

(2021) Kwan Ho Tang et al.   Cancer Discovery

Emerging Targets in Type 2 Diabetes and Diabetic Complications

(2021) Sevgican Demir et al.   Advanced Science

249-OR: A Randomized, Double-Blind Phase 2 Trial of the CXCR1/2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes

(2020) EMANUELE BOSI et al.   DIABETES

Structural basis of CXC chemokine receptor 2 activation and signalling

(2020) Kaiwen Liu et al.   NATURE

Prognostic Value of CXCR2 in Breast Cancer

(2020) Florence Boissière-Michot et al.   Cancers

Plasma protein binding as an optimisable parameter for acidic drugs

(2019) Philip Gardiner et al.   DRUG METABOLISM AND DISPOSITION

Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

(2019) Catherine de Martel et al.   Lancet Global Health

CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2

(2018) Han Xu et al.   CANCER LETTERS

CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer

(2018) Qiang Du et al.   Cancer Medicine

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

(2017) Jakob Busch-Petersen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Inflammation, metaflammation and immunometabolic disorders

(2017) Gökhan S. Hotamisligil   NATURE

CXCL1/CXCR2 signaling in pathological pain: Role in peripheral and central sensitization

(2017) Rangel L. Silva et al.   NEUROBIOLOGY OF DISEASE

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

(2017) Helen Ha et al.   Theranostics

Platelet-specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury

(2016) Khalil Bdeir et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

(2016) Colin W. Steele et al.   CANCER CELL

Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: A systematic review and meta-analysis

(2016) Yong-chao Qiao et al.   CLINICAL IMMUNOLOGY

COPD immunopathology

(2016) Gaetano Caramori et al.   Seminars in Immunopathology

Strategies toward optimization of the metabolism of a series of serotonin-4 partial agonists: investigation of azetidines as piperidine isosteres

(2016) Ronald Scott Obach et al.   XENOBIOTICA

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

(2016) Liang Wang et al.   JAMA Neurology

Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?

(2015) Isabelle St-Amour et al.   ACTA NEUROPATHOLOGICA

Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor

(2015) Yifat Amir Levy et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease

(2015) Stephen I. Rennard et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model

(2015) Dean Y. Maeda et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists

(2015) Rupert P. Austin et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions

(2015) Antonio Citro et al.   Current Diabetes Reports

Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models

(2015) Helen Ha et al.   Journal of Chemical Information and Modeling

Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease

(2015) Jae K Ryu et al.   Journal of Neuroinflammation

Inflammasomes: mechanism of action, role in disease and therapeutics

(2015) Haitao Guo et al.   NATURE MEDICINE

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD

(2015) A.M. Kirsten et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

(2015) Bruce E. Miller et al.   BMC Pharmacology & Toxicology

CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space

(2014) Mark H. M. Vries et al.   ANGIOGENESIS

Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans

(2014) Archana Kamalakar et al.   BONE

Metabolic Asthma

(2014) Miriam K. Perez et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

IL-17A Promotes the Exacerbation of IL-33-Induced Airway Hyperresponsiveness by Enhancing Neutrophilic Inflammation via CXCR2 Signaling in Mice

(2014) N. Mizutani et al.   JOURNAL OF IMMUNOLOGY

Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2

(2014) Dean Y. Maeda et al.   JOURNAL OF MEDICINAL CHEMISTRY

Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes

(2013) Oliver Soehnlein et al.   EMBO Molecular Medicine

CXCR2: a target for pancreatic cancer treatment?

(2013) Kathleen M Hertzer et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

New anti-inflammatory targets for chronic obstructive pulmonary disease

(2013) Peter J. Barnes   NATURE REVIEWS DRUG DISCOVERY

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

(2012) P. Nair et al.   CLINICAL AND EXPERIMENTAL ALLERGY

CXCL5 Gene Polymorphism Association with Diabetes Mellitus

(2012) Shirin Hasani Ranjbar et al.   Molecular Diagnosis & Therapy

Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer

(2011) Aihua Li et al.   AMERICAN JOURNAL OF PATHOLOGY

Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor

(2011) R Bertini et al.   BRITISH JOURNAL OF PHARMACOLOGY

Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor

(2011) R. Virtala et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma

(2011) Hideaki Ijichi et al.   JOURNAL OF CLINICAL INVESTIGATION

Neuroinflammation in Alzheimer's disease wanes with age

(2011) Jeroen JM Hoozemans et al.   Journal of Neuroinflammation

A common intracellular allosteric binding site for antagonists of the CXCR2 receptor

(2010) K Salchow et al.   BRITISH JOURNAL OF PHARMACOLOGY

Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases

(2010) Michelle L. Varney et al.   CANCER LETTERS

How does diabetes accelerate Alzheimer disease pathology?

(2010) Catrina Sims-Robinson et al.   Nature Reviews Neurology

Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury

(2010) D R Marsh et al.   SPINAL CORD

Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ

(2009) Pancham Bakshi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis

(2009) S. Singh et al.   CLINICAL CANCER RESEARCH

Genetic architecture of mouse skin inflammation and tumour susceptibility

(2009) David A. Quigley et al.   NATURE

Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery

(2008) Lu-Hai Wang et al.   CURRENT CANCER DRUG TARGETS

Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor- B Transcription and Evasion of Apoptosis

(2008) C. Wilson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2

(2008) D. J. Nicholls et al.   MOLECULAR PHARMACOLOGY

CXCR2 antagonists for the treatment of pulmonary disease

(2008) R.W. Chapman et al.   PHARMACOLOGY & THERAPEUTICS